N/A N=505 Impact of Family History and Decision Support on High-risk Cancer Screening
Colorectal Cancer
Primary: Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening — 219; 232 Participants — p=0.16
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=115,484 Early Detection of GEnetic Risk (EDGE)
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
N/A N=138 Previvors Recharge: A Resilience Program for Cancer Previvors
Hereditary Cancer · Mental Health Issue
Primary: Connor Davidson Resilience Scale (CDRISC) — 22.59; 23.53 score on a scale — p=.029
N/A N=47 Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling
Breast Cancer
Primary: Test Uptake: Number of Clients Who Indicated Intention to Have Genetic Testing — 14; 15; 2; 0 Participants
N/A N=967 Cancer Health Assessments Reaching Many
Hereditary Cancer Syndrome
Primary: Positive Findings for Hereditary Cancer Syndromes — 28; 8; 4; 787 Participants
N/A N=57 Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Breast Cancer
Primary: Rate of Genetic Counseling and Testing Uptake. — 18; 15; 7; 12 Participants
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
N/A N=93 Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes
Genetic Testing
Primary: Participant Satisfaction With How Educational Information is Presented in the Decision Aid — 1; 3; 29; 55 Participants
N/A N=50 Improving Germline Testing in At-Risk Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants Agreeing to Proceed With Germline Testing Among Those Approached With the Educational Intervention. — 41 Participants
N/A N=6,075 Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
Colorectal Cancer · Breast Cancer · Coronary Heart Disease
Primary: Number of Subjects Who Discussed Disease Risk With Primary Care Provider — 905; 841 Participants
N/A N=6 Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
Breast Carcinoma · Colon Carcinoma · Malignant Solid Neoplasm
Primary: Identify Cancer Patients Who Meet Criteria for Genetic Counseling and Testing — 100; 48 patients
N/A N=2,331 Connecting Families to Overcome Ovarian Cancer
Ovarian Cancer
Primary: Number of Survivors Using Website Access Code — 147; 202 Participants
Phase 2 N=195 Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
N/A N=601 Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
Advanced Malignant Neoplasm · Locally Advanced Malignant Neoplasm
Primary: Change of Scores on Cancer Genetic Knowledge Scale From Baseline to Post-genetic Education — 1.43; -0.80 score on a scale — p=<.0001
N/A N=402 HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
N/A N=112 Streamlined Genetic Testing in Prostate Cancer
Prostate Cancer
Primary: Number of Participants Completing Genetic Testing — 22; 15; 31; 39 Participants — p=0.14
Phase 2 N=37 Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
N/A N=580 An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
N/A N=50 Feasibility Clinical Study of Targeted and Genome-Wide Sequencing
Solid Tumors
Primary: Time From Patient Recruitment to Final Results ≤ 21 Days in ≥ 90% of Patients — 21 calendar days
N/A N=6,400 Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
Early Cancer Detection
Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants
N/A N=20 Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
Lynch Syndrome
Primary: Acceptability of Workbook Assessed Through Likert Score Scale — 10; 3 Participants
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
N/A N=4,732 Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
Phase 2 N=91 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Phase 2 N=74 A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants
N/A N=963 Cancer Loyalty Card Study
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001